CVRXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
CVRx, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.35+0.05 (+3.85%)
Close on Oct 19, 2026
- Market cap
- $35.80M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
57.4%
15M of 27M shares
Institutional holders
88
9 new, 18 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
3 buys · 14 sales
Net sold $614.17K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Johnson & Johnson | 4,024,861 | 15.40% | 13G (passive) amendment | Dec 31, 2025 |
| NEA Partners 10, Limited Partnership | 2,026,083 | 7.80% | 13D (active) amendment | Feb 18, 2025 |
| Kirk Nielsen | 1,760,734 | 7.20% | 13G (passive) amendment | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CVRX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Johnson & Johnson | 4,024,861 | 15.11% | $20.69M | – | 2.59% |
| NEA Management Company, LLC | 1,954,440 | 7.34% | $10.05M | −71,643 | 0.63% |
| BlackRock, Inc. | 1,245,459 | 4.67% | $6.40M | +218,900 | 0.00% |
| Royal Bank of Canada | 1,233,212 | 4.63% | $6.34M | +526,262 | 0.00% |
| GSK plc | 1,007,583 | 3.78% | $5.18M | – | 0.86% |
| Vanguard Capital Management LLC | 910,576 | 3.42% | $4.68M | −734 | 0.00% |
| Silvercrest Asset Management Group LLC | 878,109 | 3.30% | $4.51M | +306,088 | 0.03% |
| Geode Capital Management, LLC | 440,786 | 1.65% | $2.27M | +13,714 | 0.00% |
| PFM Health Sciences, LP | 369,572 | 1.39% | $1.90M | New | 0.16% |
| State Street Corp | 366,352 | 1.38% | $1.88M | +15,804 | 0.00% |
| Renaissance Technologies LLC | 230,000 | 0.86% | $1.18M | +210,700 | 0.00% |
| UBS Group AG | 224,233 | 0.84% | $1.15M | +120,423 | 0.00% |
| Tudor Investment Corp Et Al | 205,684 | 0.77% | $1.06M | +8,344 | 0.00% |
| Goldman Sachs Group Inc | 149,509 | 0.56% | $768.48K | −51,502 | 0.00% |
| Morgan Stanley | 144,977 | 0.54% | $745.18K | +5,613 | 0.00% |
| Kestra Advisory Services, LLC | 132,400 | 0.50% | $680.54K | +84,500 | 0.00% |
| Two Sigma Investments, LP | 132,398 | 0.50% | $680.53K | +18,231 | 0.00% |
| Vanguard Fiduciary Trust Co | 128,955 | 0.48% | $662.83K | +1,194 | 0.00% |
| Dimensional Fund Advisors LP | 127,971 | 0.48% | $659.87K | +75,330 | 0.00% |
| Northern Trust Corp | 124,767 | 0.47% | $641.30K | −25,356 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 88 | 15M | 57.4% | 9 / 35 | 28 / 18 | 2M | 2M |
| Q1 2026 | 99 | 15M | 55.1% | 23 / 34 | 21 / 15 | 3M | 2M |
| Q4 2025 | 92 | 15M | 57.2% | 9 / 29 | 33 / 8 | 2M | 1M |
| Q3 2025 | 93 | 14M | 52.7% | 14 / 34 | 26 / 13 | 1M | 1M |
| Q2 2025 | 92 | 15M | 54.7% | 20 / 34 | 20 / 24 | 2M | 3M |
| Q1 2025 | 96 | 16M | 60.3% | 17 / 35 | 24 / 13 | 2M | 1M |
| Q4 2024 | 93 | 15M | 56.9% | 19 / 26 | 30 / 12 | 2M | 1M |
| Q3 2024 | 86 | 14M | 53.5% | 21 / 36 | 16 / 7 | 3M | 1M |
| Q2 2024 | 73 | 13M | 49.5% | 13 / 36 | 17 / 28 | 2M | 3M |
| Q1 2024 | 88 | 14M | 54.4% | 21 / 32 | 21 / 16 | 3M | 1M |
| Q4 2023 | 83 | 13M | 48.4% | 23 / 23 | 26 / 4 | 2M | 1M |
| Q3 2023 | 64 | 12M | 46.6% | 9 / 20 | 22 / 11 | 2M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CVRX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 684,121 | 2.57% | $3.52M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 371,607 | 1.39% | $1.91M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 204,533 | 0.77% | $1.05M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 165,915 | 0.62% | $858.61K | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 156,004 | 0.59% | $801.86K | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 96,327 | 0.36% | $537.50K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 81,934 | 0.31% | $457.19K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 51,597 | 0.19% | $265.21K | 0.02% | Jun 30, 2026 |
| Ultra-Small Company Market Fund | 36,500 | 0.14% | $187.61K | 0.13% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 35,398 | 0.13% | $183.18K | 0.00% | Jul 31, 2026 |
| Fidelity Total Market Index Fund | 34,330 | 0.13% | $191.56K | 0.00% | May 31, 2026 |
| U.S. Small Cap Equity Fund | 32,926 | 0.12% | $170.39K | 0.02% | Jul 31, 2026 |
| Dimensional U.S. Small Cap ETF | 28,363 | 0.11% | $146.78K | 0.00% | Jul 31, 2026 |
| Fidelity Series Total Market Index Fund | 27,837 | 0.10% | $155.33K | 0.00% | May 31, 2026 |
| Goldman Sachs Small Cap Equity Insights Fund | 27,822 | 0.10% | $143.98K | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Kevin Hykes | PRES & CEO, Director | 284,237 | 1.07% | Mar 3, 2026 |
| Brent Binkowski | CHIEF OPERATING OFFICER | 56,514 | 0.21% | Aug 13, 2026 |
| Philip B. Adamson | Chief Medical Officer | 61,578 | 0.23% | Mar 16, 2026 |
| Gregory Morrison | CHIEF HUMAN RESOURCES OFFICER | 34,000 | 0.13% | Mar 4, 2026 |
| Jared Oasheim | CHIEF FINANCIAL OFFICER | 96,703 | 0.36% | Mar 3, 2026 |
| Paul Verrastro | CHIEF MKTG & STRAT OFFICER | 60,551 | 0.23% | Mar 3, 2026 |
| Robert Allen John | Chief Revenue Officer | 86,036 | 0.32% | Mar 3, 2026 |
| Michael D. Dale | Director | 29,005 | 0.11% | Jun 3, 2026 |
| Kirk G. Nielsen | Director | 1,918,854 | 7.20% | Jun 3, 2026 |
| Kevin J. Ballinger | Director | 8,720 | 0.03% | Jun 3, 2026 |
| Hill, Mitch C. | Director | 8,720 | 0.03% | Jun 3, 2026 |
| Martha Shadan | Director | 8,720 | 0.03% | Jun 3, 2026 |
| Mudit K. Jain | Director | 994,553 | 3.73% | Jun 3, 2026 |
| Joseph P. Slattery | Director | 39,365 | 0.15% | Jun 3, 2026 |
| & Johnson Johnson | 10% owner | 4,040,861 | 15.17% | Jan 8, 2026 |
| Johnson & Johnson Innovation - JJDC, Inc. | 10% owner | 4,024,861 | 15.11% | Jan 8, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Brent Binkowski CHIEF OPERATING OFFICER | Aug 13, 2026 | Buy | +26,223 | $2.91 | $76.31K | 56,514 |
| Brent Binkowski CHIEF OPERATING OFFICER | Aug 12, 2026 | Sale(10b5-1 plan) | −1,309 | $2.55 | $3.34K | 30,291 |
| Mudit K. Jain Director | Jun 1, 2026 | Award | +8,720 | – | – | 14,370 |
| Martha Shadan Director | Jun 1, 2026 | Award | +8,720 | – | – | 8,720 |
| Kirk G. Nielsen Director | Jun 1, 2026 | Award | +8,720 | – | – | 8,720 |
| Kevin J. Ballinger Director | Jun 1, 2026 | Award | +8,720 | – | – | 8,720 |
| Hill, Mitch C. Director | Jun 1, 2026 | Award | +8,720 | – | – | 8,720 |
| Michael D. Dale Director | Jun 1, 2026 | Award | +29,005 | – | – | 29,005 |
| Joseph P. Slattery Director | Jun 1, 2026 | Award | +8,720 | – | – | 39,365 |
| Philip B. Adamson Chief Medical Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −1,262 | $7.90 | $9.97K | 61,578 |
| Gregory Morrison CHIEF HUMAN RESOURCES OFFICER | Mar 2, 2026 | Award | +34,000 | – | – | 34,000 |
| Kevin Hykes PRES & CEO, Director | Mar 2, 2026 | Sale(10b5-1 plan) | −7,763 | $7.90 | $61.33K | 284,237 |
| Jared Oasheim CHIEF FINANCIAL OFFICER | Mar 2, 2026 | Sale(10b5-1 plan) | −1,744 | $7.90 | $13.78K | 96,703 |
| Robert Allen John Chief Revenue Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −3,964 | $7.90 | $31.32K | 86,036 |
| Paul Verrastro CHIEF MKTG & STRAT OFFICER | Mar 2, 2026 | Sale(10b5-1 plan) | −1,284 | $7.90 | $10.14K | 60,551 |
| Philip B. Adamson Chief Medical Officer | Feb 27, 2026 | Award | +41,000 | – | – | 62,840 |
| Brent Binkowski CHIEF OPERATING OFFICER | Feb 27, 2026 | Award | +15,000 | – | – | 31,600 |
| Kevin Hykes PRES & CEO, Director | Feb 27, 2026 | Award | +159,000 | – | – | 292,000 |
| Jared Oasheim CHIEF FINANCIAL OFFICER | Feb 27, 2026 | Award | +61,000 | – | – | 98,447 |
| Robert Allen John Chief Revenue Officer | Feb 27, 2026 | Award | +35,000 | – | – | 90,000 |
| Paul Verrastro CHIEF MKTG & STRAT OFFICER | Feb 27, 2026 | Award | +45,000 | – | – | 61,835 |
| Mudit K. Jain Director | Feb 20, 2026 | Buy | +46,800 | $6.36 | $297.65K | 980,183 |
| Mudit K. Jain Director | Feb 18, 2026 | Buy | +600 | $4.64 | $2.78K | 5,650 |
| Johnson & Johnson Innovation - JJDC, Inc. 10% owner | Nov 26, 2025 | Sale | −6,337 | $10.03 | $63.56K | 4,024,861 |
| & Johnson Johnson 10% owner | Nov 26, 2025 | Sale | −6,337 | $10.03 | $63.56K | 4,040,861 |
| Johnson & Johnson Innovation - JJDC, Inc. 10% owner | Nov 25, 2025 | Sale | −16,000 | $10.03 | $160.48K | 4,031,198 |
| & Johnson Johnson 10% owner | Nov 24, 2025 | Sale | −2,200 | $10.06 | $22.13K | 4,047,198 |
| & Johnson Johnson 10% owner | Nov 21, 2025 | Sale | −500 | $10.00 | $5.00K | 4,049,398 |
| & Johnson Johnson 10% owner | Nov 12, 2025 | Sale | −1,000 | $10.00 | $10.00K | 4,049,898 |
| Johnson & Johnson Innovation - JJDC, Inc. 10% owner | Nov 7, 2025 | Sale | −200 | $10.00 | $2.00K | 4,050,898 |
| Johnson & Johnson Innovation - JJDC, Inc. 10% owner | Nov 6, 2025 | Sale | −52,332 | $10.21 | $534.31K | 4,051,098 |
| Brent Binkowski CHIEF OPERATING OFFICER | Aug 11, 2025 | Award | +16,600 | – | – | 16,600 |
| Kirk G. Nielsen Director | May 15, 2025 | Buy | +10,966 | $5.45 | $59.76K | 1,910,134 |
| Kirk G. Nielsen Director | May 14, 2025 | Buy | +61,200 | $5.23 | $320.08K | 1,899,168 |
| Kirk G. Nielsen Director | May 13, 2025 | Buy | +101,413 | $5.29 | $536.47K | 1,837,968 |
| Mudit K. Jain Director | May 13, 2025 | Buy | +150 | $5.26 | $789 | 5,050 |
| Kirk G. Nielsen Director | May 12, 2025 | Buy | +25,200 | $4.79 | $120.71K | 1,736,555 |
| Mudit K. Jain Director | May 12, 2025 | Buy | +1,500 | $4.66 | $6.99K | 4,900 |
| Kevin Hykes PRES & CEO, Director | May 12, 2025 | Buy | +5,000 | $4.84 | $24.20K | 133,000 |
| Jared Oasheim CHIEF FINANCIAL OFFICER | Feb 28, 2025 | Award | +22,000 | – | – | 37,447 |
| Robert Allen John Chief Revenue Officer | Feb 28, 2025 | Award | +55,000 | – | – | 55,000 |
| Kevin Hykes PRES & CEO, Director | Feb 28, 2025 | Award | +98,000 | – | – | 128,000 |
| Philip B. Adamson Chief Medical Officer | Feb 28, 2025 | Award | +20,000 | – | – | 20,000 |
| Paul Verrastro CHIEF MKTG & STRAT OFFICER | Feb 28, 2025 | Award | +16,000 | – | – | 16,835 |
| Paul Verrastro CHIEF MKTG & STRAT OFFICER | Nov 21, 2024 | Gift | −1,040 | – | – | 835 |
| Paul Verrastro CHIEF MKTG & STRAT OFFICER | Nov 19, 2024 | Option exercise | +2,500 | $5.14 | $12.85K | 3,305 |
| Paul Verrastro CHIEF MKTG & STRAT OFFICER | Nov 19, 2024 | Sale | −1,430 | $13.58 | $19.42K | 1,875 |
| Joseph P. Slattery Director | Aug 15, 2024 | Buy | +3,000 | $8.10 | $24.30K | 30,645 |
| Joseph P. Slattery Director | Aug 8, 2024 | Buy | +3,000 | $8.24 | $24.72K | 27,645 |
| Joseph P. Slattery Director | Aug 6, 2024 | Buy | +2,500 | $9.09 | $22.73K | 24,645 |
| Kevin Hykes PRES & CEO, Director | Aug 5, 2024 | Buy | +30,000 | $8.36 | $250.80K | 30,000 |
| Craig E. Palmer SVP, U.S. SALES | Mar 25, 2024 | Option exercise | +379 | $0.24 | $91 | 674 |
| Craig E. Palmer SVP, U.S. SALES | Mar 25, 2024 | Option exercise | +404 | $0.24 | $97 | 1,078 |
| Craig E. Palmer SVP, U.S. SALES | Mar 25, 2024 | Option exercise | +151 | $0.24 | $36 | 1,229 |
| Johnson & Johnson Innovation - JJDC, Inc. 10% owner | Feb 29, 2024 | Option exercise | +79 | $5.14 | $406 | 4,103,430 |
| Johnson & Johnson Innovation - JJDC, Inc. 10% owner | Feb 29, 2024 | Option exercise | +158 | $0.24 | $38 | 4,099,733 |
| Johnson & Johnson Innovation - JJDC, Inc. 10% owner | Feb 29, 2024 | Option exercise | +189 | $0.24 | $45 | 4,099,922 |
| Johnson & Johnson Innovation - JJDC, Inc. 10% owner | Feb 29, 2024 | Option exercise | +165 | $0.24 | $40 | 4,100,087 |
| Johnson & Johnson Innovation - JJDC, Inc. 10% owner | Feb 29, 2024 | Option exercise | +118 | $0.24 | $28 | 4,100,205 |
| Johnson & Johnson Innovation - JJDC, Inc. 10% owner | Feb 29, 2024 | Option exercise | +71 | $0.24 | $17 | 4,100,276 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Ali Behbahani Officer | Nov 29, 2024 | 21,837 | $334.11K | Nov 29, 2024 | STOCK OPTION EXERCISE |
| Verrastro Paul Officer | Nov 19, 2024 | 1,430 | $19.42K | Nov 19, 2024 | Exercise of options under a registered plan |
| Ali Behbahani Officer | Nov 18, 2024 | 9 | $127 | Nov 18, 2024 | STOCK OPTION EXERCISE |
| New Enterprise Associates VIII, LP Affiliate | Nov 5, 2024 | 171,071 | $2.57M | Nov 5, 2024 | Private placement |
| NEA Enterprise Associates 8A, LP Affiliate | Nov 5, 2024 | 173,388 | $2.61M | Nov 5, 2024 | Private placement |
| Craig E. Palmer Officer | Jul 26, 2024 | 18,243 | $175.06K | Jul 26, 2024 | STOCK OPTION EXERCISE |
| Craig E. Palmer Officer | Jul 25, 2024 | 11,880 | $113.91K | Jul 25, 2024 | STOCK OPTION EXERCISE |
| Craig E. Palmer Officer | Jul 24, 2024 | 2,000 | $19.22K | Jul 24, 2024 | STOCK OPTION EXERCISE |
| Craig E. Palmer Officer | Jul 23, 2024 | 2,000 | $20.14K | Jul 23, 2024 | STOCK OPTION EXERCISE |
| Craig E. Palmer Officer | Jul 22, 2024 | 3,930 | $37.72K | Jul 22, 2024 | STOCK OPTION EXERCISE |
| Craig E. Palmer Officer | Jul 16, 2024 | 7,152 | $70.48K | Jul 16, 2024 | STOCK OPTION EXERCISE |
| Verrastro Paul Officer | Feb 20, 2024 | 2,545 | $55.75K | Feb 20, 2024 | Exercise of options under a registered plan |
| John M. Nehra Director | Aug 10, 2023 | 10,560 | $182.69K | Aug 10, 2023 | STOCK OPTION EXERCISE |